Don’t Be Fooled By Gain in aTyr Pharma Inc. [LIFE] Stock

In a recent bid aTyr Pharma Inc. [LIFE] faced a contemporary bid of $4.43 yielding a 19.94% incline where 0.12 million shares have exchanged hands over the last week. LIFE amount got a boost by 5.34% or $0.22 versus $4.21 at the end of the prior session. This change led market cap to move at 43.07M, putting the price 108.22% below the 52-week high and -41.80% above the 52-week low. The company’s stock has a normal trading capacity of 0.12 million shares while the relative volume is 4.45.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 12, November 2020, aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update. According to news published on Yahoo Finance, Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year.

Analyst Birdseye View:

The most recent analyst activity for aTyr Pharma Inc. [NASDAQ:LIFE] stock was on March 04, 2020, when it was Initiated with a Buy rating from ROTH Capital, which also raised its 12-month price target on the stock to $15. Before that, on August 17, 2020, H.C. Wainwright Recapitulated a Buy rating and elevated its amount target to $13. On March 02, 2020, Oppenheimer Initiated an Outperform rating and boosted its price target on this stock to $8. On February 14, 2018, JP Morgan Downgrade an Underweight rating. On September 07, 2017, Piper Jaffray Initiated an Overweight rating and increased its price target to $7. On December 13, 2016, JP Morgan Downgrade a Neutral rating. On December 16, 2015, Citigroup Initiated a Neutral rating. On June 01, 2015, JP Morgan Initiated an Overweight rating and improved its amount target to $44.

In the past 52 weeks of trading, this stock has oscillated between a low of $2.13 and a peak of $7.62. Right now, the middling Wall Street analyst 12-month amount mark is $13.00. At the most recent market close, shares of aTyr Pharma Inc. [NASDAQ:LIFE] were valued at $4.43.


aTyr Pharma Inc. [NASDAQ:LIFE] most recently reported quarterly sales of 148.0 million, which represented growth of -50.00%. This publicly-traded organization’s revenue is $9,591 per employee, while its income is -$536,432 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -53.08, -86.09, -55.75 and -72.25 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 35.64 and the whole liability to whole assets at 32.42. It shows enduring liability to the whole principal at 6.80 and enduring liability to assets at 0.06 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 4.02 points at 1st support level, the second support level is making up to 3.82. But as of 1st resistance point, this stock is sitting at 4.31 and at 4.40 for 2nd resistance point.

aTyr Pharma Inc. [LIFE] reported its earnings at -$0.68 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.74/share signifying the difference of 0.06 and 8.10% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.69 calling estimates for -$0.73/share with the difference of 0.04 depicting the surprise of 5.50%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for aTyr Pharma Inc. [NASDAQ:LIFE] is 4.80. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.41. Now if looking for a valuation of this stock’s amount to sales ratio it’s 33.16 and it’s amount to book ratio is 0.77.

Insider Stories

The most recent insider trade was by CLARKE JOHN K, Director, and it was the sale of 7260.0 shares on Sep 02. CLARKE JOHN K, the Director, completed a sale of 100.0 shares on Aug 28. On Aug 27, CLARKE JOHN K, Director, completed a sale of 5440.0 shares.